NCCAM turns five
This article was originally published in The Tan Sheet
National Center for Complementary & Alternative Medicine celebrates its fifth anniversary by announcing the launch of its second five-year strategic plan, NIH center says during recent advisory council meeting. Draft of the plan will be released in the fall. NCCAM director Stephen Straus, MD, cites the center's research portfolio containing "over 300 projects" and including the "largest ever placebo-controlled clinical trials of popular dietary supplements like glucosamine for degenerative arthritis and ginkgo biloba for dementia" among NCCAM's noteworthy accomplishments. Straus also notes that "most importantly, a body of data is emerging from NCCAM's investments in research that is informing public policy and helping guide practices"...
You may also be interested in...
Future research on complementary and alternative medicine should include clinical testing on interactions between dietary supplements and conventional medications, according to one toxicology expert
When asked about an inspector general report that found hospitals are struggling with tests and resources, and are looking to the federal government to help facilitate more efficient distribution of medical devices to fight the COVID-19 crisis, President Trump attacked the report as a political hit from an Obama holdover.
Japanese medical device manufacturer Terumo Corp. promoted senior management execs; MiMedx Group, developer of human placental tissue allografts, raised exec to CFO; and more.